News by Subject Medicine & Health

At the organization responsible for certifying the training and skills of US urologists, achieving and maintaining diversity, equity and inclusion is more than just a "numbers game," according to a special article in Urology Practice®, an Official Journal of the American Urological Association (AUA). The journal is published in the Lippincott portfolio by Wolters Kluwer.

This new review by the International Osteoporosis Foundation (IOF) and European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) CKD-MBD working group provides concise recommendations, with a clear management algorithm, to support clinicians' knowledge and confidence in managing osteoporosis in their patients with chronic kidney disease stages 4-5D.

A small regulatory RNA found in many problematic bacteria, including Escherichia coli, appears to be responsible for managing the response of these bacteria to environmental stresses. Professor Charles Dozois from Institut national de la recherche scientifique (INRS) and doctoral student Hicham Bessaiah see a promising avenue for more effective treatment of antibiotic-resistant bacteria. Their results have been published in the journal PLOS Pathogens.

Using a novel imaging approach, researchers discovered that the journey of the egg and the embryo through the fallopian tube is more dynamic and complex than previously thought.

Men over 60 with low-risk prostate cancer could spend ten years with no active treatment, have a better sex life as a result, yet still be very unlikely to die from the disease, new research has found.

Using an existing drug for late-stage kidney cancer at an earlier stage of the disease could reduce the risk of cancer recurring by a third, according to new research.

Obese patients with a form of advanced prostate cancer survive longer than overweight and normal weight patients, new research has found.

Being immersed in a stunning 'virtual' Icelandic landscape can reduce the pain caused by uncomfortable medical procedures, new research has found.

A new class of drug successfully targets treatment-resistant prostate cancers and prolongs the life of patients. The treatment delivers beta radiation directly to tumour cells, is well tolerated by patients and keeps them alive for longer than standard care, found a phase 3 trial to be presented at the European Association of Urology congress, EAU21, today.